Emergent BioSolutions Inc.
For the period ended Aug 5, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Aug 5, 2026 · Filed Aug 5, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · RESTRUCTURING UPDATES
RESTRUCTURING UPDATES
Efforts aim to improve overall cost structure, drive efficiencies and align resourcing to the current needs of the organization; includes reduction of approximately 90 roles
Creation of a new Growth organization that integrates the capabilities of R&D, Business Development, Strategy into one function led by Stephanie Duatschek, Senior Vice President, Chief Global Strategy & Franchise Development Officer, who will assume the role of Executive Vice President, Chief Growth Officer, with responsibility for the Company’s strategic growth
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.